Irene Stefanaki

14PUBLICATIONS
26CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer geneticsPharmacogenomicsGene and molecular therapyMedical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jun 16, 2026
Drug survival of bimekizumab, guselkumab, and risankizumab after secondary IL-17 inhibitor failure.

|Nov 14, 2025
Genetic susceptibility in early-onset melanoma: An observational Greek cohort study.

Eftychia Chatziioannou, Katerina Kypreou, Irene Stefanaki

|Nov 14, 2025
Switching within the class of IL-23 inhibitors for the treatment of psoriasis: A systematic review.

Ioannis-Alexios Koumprentziotis, Irene Stefanaki, Alexander Stratigos

|Sep 27, 2025
Long-Term Outcomes of Guselkumab and Risankizumab for the Management of Moderate-to-Severe Psoriasis in the Elderly: Results from a Real-World Retrospective Study.

Ioannis-Alexios Koumprentziotis, Irene Stefanaki, Eleni Routsi

|Jun 05, 2025
Guselkumab Is Effective for the Management of Scalp Psoriasis in Both Biologic-Naïve and Biologic-Experienced Patients: Results From a Real-World, Retrospective Study.

Ioannis-Alexios Koumprentziotis, Irene Stefanaki, Natalia Rompoti

|Nov 22, 2024
Number of melanoma deaths over time in relation to tumour thickness: Data from a Melanoma Unit Reference Center.

I A Stratigos, M Delitheos, K Kypreou

Pageof 3

Frequent Collaborators

7 joint publications

Electra Nicolaidou

4 joint publications

Ioannis-Alexios Koumprentziotis

4 joint publications

Natalia Rompoti

3 joint publications

Maria Concetta Fargnoli